TLRY

Company Overview — What Does Tilray Brands, Inc. Do?

Tilray Brands Inc. engages in the research, cultivation, production, marketing, and distribution of medical cannabis products. It operates through five segments: Cannabis Business, Distribution Business, Beverage Alcohol Business, Wellness Business, and Business Under Development. The company provides medical and adult-use cannabis products; pharmaceutical and wellness products; beverage alcohol products; and hemp-based food and other wellness products. It offers its products to retailers, wholesalers, patients, physicians, pharmacies, clinics, hospitals, governments, and researchers. The company operates Tilray Medical, a medical platform that provides GMP-certified flowers, oils, vapes, edibles, and topicals. It has operations in Canada, the United States, Europe, Australia, New Zealand, Latin America, and internationally. The company was formerly known as Tilray, Inc. Tilray Brands Inc. was incorporated in 2018 and is headquartered in New York, New York. Tilray Brands, Inc. (TLRY) is classified as a small-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Irwin D. Simon and employs approximately 1,700 people. With a market capitalization of $714M, TLRY is one of the notable companies in the Healthcare sector.

Tilray Brands, Inc. (TLRY) Stock Rating — Reduce (April 2026)

As of April 2026, Tilray Brands, Inc. receives a Reduce rating with a composite score of 38.1/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.TLRY ranks #2,987 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Tilray Brands, Inc. ranks #429 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

TLRY Stock Price and 52-Week Range

Tilray Brands, Inc. (TLRY) currently trades at $6.82. The stock gained $0.10 (1.4%) in the most recent trading session. The 52-week high for TLRY is $15.70, which means the stock is currently trading -56.6% from its annual peak. The 52-week low is $0.35, putting the stock 1843.9% above its annual trough. Recent trading volume was 129K shares, suggesting relatively thin trading activity.

Is TLRY Overvalued or Undervalued? — Valuation Analysis

Tilray Brands, Inc. (TLRY) carries a value factor score of 29/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 0.49x, versus the sector average of 2.75x. The price-to-sales ratio is 0.92x, compared to 1.66x for the average Healthcare stock.

At current multiples, Tilray Brands, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Tilray Brands, Inc. Profitability — ROE, Margins, and Quality Score

Tilray Brands, Inc. (TLRY) earns a quality factor score of 26/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -56.4%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -41.5% versus the sector average of -33.1%.

On a margin basis, Tilray Brands, Inc. reports gross margins of 27.1%, compared to 71.5% for the sector. The operating margin is -107.8% (sector: -66.1%). Net profit margin stands at -114.7%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -2.0% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

TLRY Debt, Balance Sheet, and Financial Health

Tilray Brands, Inc. has a debt-to-equity ratio of 36.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 2.79x, indicating strong short-term liquidity.

TLRY has a beta of 1.90, meaning it is more volatile than the broader market — a $10,000 investment in TLRY would be expected to move 90.1% more than the S&P 500 on any given day. The stability factor score for Tilray Brands, Inc. is 15/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Tilray Brands, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Tilray Brands, Inc. reported revenue of $820M and earnings per share (EPS) of $-0.24. Net income for the quarter was $-861M. Gross margin was 27.1%. Operating income came in at $-807M.

In Q3 2026, Tilray Brands, Inc. reported revenue of $207M and earnings per share (EPS) of $-0.24. Net income for the quarter was $-25M. Gross margin was 26.6%. Revenue grew 11.3% year-over-year compared to Q3 2025. Operating income came in at $-26M.

In Q2 2026, Tilray Brands, Inc. reported revenue of $218M and earnings per share (EPS) of $-0.41. Net income for the quarter was $-44M. Gross margin was 26.4%. Revenue grew 3.1% year-over-year compared to Q2 2025. Operating income came in at $-22M.

In Q1 2026, Tilray Brands, Inc. reported revenue of $210M and earnings per share (EPS) of $0.00. Net income for the quarter was $2M. Gross margin was 27.4%. Revenue grew 4.7% year-over-year compared to Q1 2025. Operating income came in at $2M.

Over the past 8 quarters, Tilray Brands, Inc. has demonstrated a growth trajectory, with revenue expanding from $200M to $820M. Investors analyzing TLRY stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

TLRY Dividend Yield and Income Analysis

Tilray Brands, Inc. (TLRY) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

TLRY Momentum and Technical Analysis Profile

Tilray Brands, Inc. (TLRY) has a momentum factor score of 67/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 34/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 41/100 reflects moderate short selling activity.

TLRY vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Tilray Brands, Inc. (TLRY) ranks #429 out of 838 stocks based on the Blank Capital composite score. This places TLRY in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing TLRY against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full TLRY vs S&P 500 (SPY) comparison to assess how Tilray Brands, Inc. stacks up against the broader market across all factor dimensions.

TLRY Next Earnings Date

No upcoming earnings date has been announced for Tilray Brands, Inc. (TLRY) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy TLRY? — Investment Thesis Summary

The quantitative profile for Tilray Brands, Inc. suggests caution. The quality score of 26/100 flags below-average profitability. The value score of 29/100 indicates premium valuation. Price momentum is positive at 67/100, suggesting the trend favors buyers. High volatility (stability score 15/100) increases portfolio risk.

In summary, Tilray Brands, Inc. (TLRY) earns a Reduce rating with a composite score of 38.1/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on TLRY stock.

Related Resources for TLRY Investors

Explore more research and tools: TLRY vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare TLRY head-to-head with peers: TLRY vs AZN, TLRY vs SLGL, TLRY vs VMD.